Aclid Company Profile

Background

Overview

Founded in 2021, Aclid is a biotechnology company specializing in security and compliance automation. The company's mission is to make genetic engineering safer and more accessible by providing real-time screening and verification solutions for gene and oligo synthesis providers. Aclid plays a significant role in the biotechnology industry by addressing the growing need for robust biosecurity measures amid the rapid expansion of synthetic biology.

Key Strategic Focus

Core Objectives

Aclid focuses on automating biosecurity and compliance processes for the biotechnology sector. Its primary objectives include:

Real-Time Screening: Delivering comprehensive threat assessments and risk profiles for DNA and RNA sequences within seconds, enabling immediate monitoring and prevention of misuse.

Customer Verification: Automating the verification of licenses, registrations, and biosafety guidelines to ensure legitimate use, thereby reducing manual follow-ups and enhancing efficiency.

Primary Markets

Aclid serves a diverse clientele, including:

Biotech Manufacturers: Assisting in compliance with US screening regulations, biosafety guidelines, and trade restrictions.

Government Agencies: Providing tools for responsible research and biosecurity management.

Financials and Funding

Funding History

Seed Funding (October 2023): Aclid secured an oversubscribed seed financing round of $3.3 million, led by 2048 Ventures and IA Ventures.

Utilization of Capital

The funds are intended to meet customer demand for Aclid's real-time screening and verification platform, enhancing its capabilities and expanding its market reach.

Technological Platform and Innovation

Proprietary Technologies

Aclid's platform offers:

Real-Time Screening: Rapid assessment of DNA and RNA sequences to identify pathogenic and toxic elements.

Automated Compliance Checks: Streamlining the compliance process by managing customer follow-ups and reducing false alarms.

Scientific Methodologies

The platform integrates advanced algorithms and data analysis techniques to provide accurate and efficient biosecurity assessments, ensuring compliance with evolving regulations and guidelines.

Leadership Team

Key Executives

Harris H. Wang, Ph.D.: Scientific Founder. Associate Professor of Systems Biology at Columbia University, leading research in microbiome and genome engineering.

Kevin Flyangolts: Founder & Chief Executive Officer. Former Engineering Lead at Umbrella, with a background in engineering and biosecurity.

Advisors

Todd Peterson, Ph.D.: Founder and Principal of GenApex Bio; former CTO of Synthetic Genomics and board chair of the International Gene Synthesis Consortium.

Neeraj Rao: Former Senior Director at Battelle, leading synthetic biology biosecurity division and business development for clinical metagenomics, wastewater surveillance, and DNA-based data storage.

Competitor Profile

Market Insights and Dynamics

The biosecurity and compliance automation market is experiencing significant growth due to the increasing adoption of synthetic biology and the need for stringent regulatory compliance. Aclid operates in a niche segment, providing specialized solutions for gene synthesis providers.

Competitor Analysis

While specific direct competitors are not extensively detailed, companies offering similar services include:

Cloudbyz: Provides safety and pharmacovigilance solutions for pharmaceutical and life science companies.

SciNote: Offers a cloud-based electronic lab notebook with built-in inventory, compliance, and team management tools.

Strategic Collaborations and Partnerships

Aclid collaborates with leading biotech manufacturers and government agencies to enhance biosecurity measures and compliance processes. These partnerships strengthen its market position and innovation capacity.

Operational Insights

Competitive Advantages

Automation: Aclid's platform automates over 80% of the compliance process, reducing manual efforts and increasing efficiency.

Real-Time Capabilities: The ability to deliver rapid threat assessments and customer verifications sets Aclid apart from competitors relying on manual processes.

Strategic Opportunities and Future Directions

Expansion Plans

Aclid aims to expand its customer base by targeting larger manufacturers and replacing in-house systems with its automated solutions.

Innovation Focus

The company continues to invest in enhancing its platform's capabilities, integrating advanced technologies to address evolving biosecurity challenges and regulatory requirements.